Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company headquartered in New York, NY, USA. The company is dedicated to advancing brain health by developing innovative oral medicines for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

Anavex's primary focus is on central nervous system (CNS) diseases with high unmet medical needs. Its lead investigational drug candidate, blarcamesine (ANAVEX®2-73), is being developed for conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome. The company's pipeline also includes ANAVEX®3-71 for schizophrenia and ANAVEX®1-41 for other CNS disorders like depression, with preclinical programs extending to pain and certain cancers.

Christopher U. Missling serves as the President and CEO. In February 2026, Anavex reported a cash position of $131.7 million, with a projected cash runway extending beyond three years. The company received positive feedback from the FDA in January 2026 regarding potential pathways for a New Drug Application (NDA) for Alzheimer's disease. However, in December 2025, Anavex requested the European Medicines Agency (EMA) to re-examine its negative opinion on the marketing authorization application for blarcamesine in early Alzheimer's disease. Recent data from the AD-004 Phase IIb/III trial for blarcamesine in early Alzheimer's disease, presented in March 2026, indicated a correlation between treatment effect and preservation of brain volume. As a clinical-stage biotechnology company, Anavex currently has no approved products or revenue, operating under a high-risk, high-reward business model dependent on research and development success.